- Home
- DAL vs ONC Comparison
DAL vs ONC Comparison
Compare DAL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAL
- ONC
- Stock Information
- Founded
- DAL 1924
- ONC 2010
- Country
- DAL United States
- ONC Switzerland
- Employees
- DAL N/A
- ONC N/A
- Industry
- DAL Air Freight/Delivery Services
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- DAL Consumer Discretionary
- ONC Health Care
- Exchange
- DAL Nasdaq
- ONC Nasdaq
- Market Cap
- DAL 34.7B
- ONC 31.5B
- IPO Year
- DAL N/A
- ONC N/A
- Fundamental
- Price
- DAL $60.53
- ONC $311.91
- Analyst Decision
- DAL Strong Buy
- ONC Strong Buy
- Analyst Count
- DAL 13
- ONC 9
- Target Price
- DAL $67.69
- ONC $335.78
- AVG Volume (30 Days)
- DAL 7.5M
- ONC 419.8K
- Earning Date
- DAL 10-09-2025
- ONC 08-06-2025
- Dividend Yield
- DAL 1.24%
- ONC N/A
- EPS Growth
- DAL N/A
- ONC N/A
- EPS
- DAL 6.88
- ONC N/A
- Revenue
- DAL $61,925,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- DAL N/A
- ONC $865.19
- Revenue Next Year
- DAL $5.89
- ONC $21.12
- P/E Ratio
- DAL $8.80
- ONC N/A
- Revenue Growth
- DAL 3.01
- ONC 47.33
- 52 Week Low
- DAL $34.74
- ONC $170.99
- 52 Week High
- DAL $69.98
- ONC $330.63
- Technical
- Relative Strength Index (RSI)
- DAL 68.51
- ONC N/A
- Support Level
- DAL $52.88
- ONC N/A
- Resistance Level
- DAL $59.52
- ONC N/A
- Average True Range (ATR)
- DAL 1.57
- ONC 0.00
- MACD
- DAL 0.63
- ONC 0.00
- Stochastic Oscillator
- DAL 89.24
- ONC 0.00
About DAL Delta Air Lines Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.